• Technology
  • Applications
    • AML – MRD
    • Mutagenesis
    • Collaborate
  • Resources
    • Publications
    • Posters
    • Safety
    • Patents
  • Company
    • Our Team
    • Careers
    • Events
    • News
  • Contact
TwinStrand Biosciences
  • Technology
  • Applications
    • AML – MRD
    • Mutagenesis
    • Collaborate
  • Resources
    • Publications
    • Posters
    • Safety
    • Patents
  • Company
    • Our Team
    • Careers
    • Events
    • News
  • Contact

What was hidden
is now
revealed.

TwinStrand Duplex SequencingTM Technology

 

Learn More

News


TwinStrand Biosciences Appoints Dr. Gary Gilliland to Board of Directors – 01/06/2021

 

 

SEE ALL NEWS

Virtual Events


American Society of Hematology (ASH 2020) December 5-8, 2020 Poster Presentation

 

 

SEE ALL EVENTS

Science


Direct Quantification of In Vivo Mutagenesis and Carcinogenesis Using Duplex Sequencing

 

SEE MORE PUBLICATIONS

It’s a simple but revolutionary idea—overcome the limitations of standard sequencing by independently tracking both strands of individual DNA molecules and comparing the results to eliminate errors.

 

Using a combination of proprietary biochemistry and cloud-based informatics, Duplex Sequencing greatly increases the resolution of next generation sequencing by reducing error rates from about 1-in-100 to 1-in-10 million.

 

Now even the rarest variants can be detected with unparalleled sensitivity and unprecedented specificity.

A complete solution

Overcoming obscurity in 5 Days

TwinStrand Duplex Sequencing technology is an end-to-end solution, from pre-sequencing biochemistry to post-sequencing bioinformatics.

 

 

(click to expand)

Superior error correction

Using standard sequencing systems and an easy-to-adopt workflow, errors are reduced to below one artifactual mutation per ten million nucleotides.


(click to expand)

 

Learn More

Imagine the possibilities

Duplex Sequencing can inform critical decisions in clinical medicine, public health, and other fields of science—on a faster time scale, where actions are most impactful.

 

Cancers can be detected and treated sooner. Drug resistance can be identified earlier. Residual diseases can be confirmed quickly. Mutagenetic chemicals can be recognized faster.

 

Learn More

Put Duplex Sequencing to work for you.

To get started, click “contact us” below to tell us about your current work and to learn how our Duplex Sequencing technology will revolutionize your research.

 

CONTACT US

 

 

 

TwinStrand Biosciences, Inc.
3131 Elliott Ave, Suite 750 • Seattle, WA 98121 • USA
+1 (877) 202-TWIN

 

For Research Use Only. Not for use in diagnostic procedures.

©2020 TwinStrand Biosciences, Inc. All rights reserved. All trademarks are the property of TwinStrand Biosciences, Inc. or their respective owners.  Legal Notices

  

This website uses cookies to improve your experience. Read More. You can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

American Society of Hematology (ASH)

December 5-8, 2020 – Virtual

 

Poster Presentation

 

“Duplex Sequencing with Patient-Specific Hybrid Capture Panels Reveals Ultra-Low Frequency Measurable Residual Disease in Pediatric Acute Myeloid Leukemia”

 

Presented by Jake Higgins, Senior Scientist – December 6, 2020 7:00 a.m.-3:30 p.m. PST

 

Conference Website

 

Society of Toxicology (SOT)

March 10-14, 2019 – Baltimore, MD

 

Poster Presentations

 

 

View Poster

 

 

Conference Website

 

AACR Annual Meeting – San Diego, CA

March 29-April 3, 2019

 

Poster Presentations

 

 

View Poster

 

 

View Poster

Presentations by CEO Jesse Salk, MD, PhD – AGBT 2020

Ultra-Sensitive Residual Leukemia Detection with Patient-Specific Dupex Sequencing